The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Mechanisms of constitutive NF‐κB activation in human prostate cancer cells
Abstract
BACKGROUND: Activation of the NF‐κB transcription factor has been previously demonstrated in two androgen receptor negative prostate cancer cell lines. We wished to extend this work to additional prostate cancer cells and to characterize the mechanisms responsible for constitutive NF‐κB activation. METHODS: Electrophoretic mobility shift assays were performed to measure NF‐κB DNA‐binding activity in prostate cancer cell lines, and immunohistochemistry was performed to detect nuclear localization of NF‐κB in prostate cancer tissues. Western blot analysis was used to study the status of IκBα. Transient transfection assays were employed to characterize the contributions of IκB kinase (IKK), MAPK kinase kinases (MAPKKKs), androgen receptor (AR), and tyrosine phosphorylation to the constitutive activation of NF‐κB in the prostate cancer cell lines. RESULTS: Constitutive NF‐κB activity was observed in AR‐negative cell lines as well as in the prostate cancer patient samples, but was not present in AR positive cells. A “super‐repressor” IκBα, as well as dominant negative forms of IKKβ and NF‐κB‐inducing kinase (NIK), and tyrosine kinase inhibition were able to suppress NF‐κB activity in the cells with constitutive activation. CONCLUSIONS: The constitutive activation of NF‐κB observed in prostate cancer cells is likely due to a signal transduction pathway involving tyrosine kinases, NIK, and IKK activation. Prostate 52:183–200, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Control of IκB-α Proteolysis by Site-Specific, Signal-Induced Phosphorylation
Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., & Siebenlist, U. (1995) · Science · doi:10.1126/science.7878466 · Cited by 1,434
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
Catz, S. D., & Johnson, J. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204926 · Cited by 538
Cited by
Nuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer
Fuchs, S. Y., Spiegelman, V. S., & Suresh Kumar, K. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207389 · Cited by 310
Xu, C., Shen, G., Chen, C., Gélinas, C., & Kong, A.-N. T. (2005) · Oncogene · doi:10.1038/sj.onc.1208656 · Cited by 301
Self-citationNuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
Multitargeted therapy of cancer by ellagitannins
Heber, D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.043 · Cited by 227
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells
Meng, Q., Peng, Z., Chen, L., Si, J., Dong, Z., & Xia, Y. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.002 · Cited by 39
Metadata
- Authors
- Suh, J., Payvandi, F., Edelstein, L. C., Amenta, P. S., Zong, W., Gélinas, C., & Rabson, A. B.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2002-06-17
- Volume
- 52
- Issue
- 3
- Pages
- 183-200
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2075172606
- Cited by
- 233
- References
- 3
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.